Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Current Signal: SELL (auto-tracking)
-0.20% $5.02
America/New_York / 28 mar 2024 @ 16:00
FUNDAMENTALS | |
---|---|
MarketCap: | 180.99 mill |
EPS: | -1.420 |
P/E: | -3.54 |
Earnings Date: | May 08, 2024 |
SharesOutstanding: | 36.05 mill |
Avg Daily Volume: | 0.242 mill |
RATING 2024-03-28 |
---|
B+ |
Neutral |
RATINGS | ||
---|---|---|
Rating CashFlow: | Buy | |
Return On Equity: | Strong Sell | |
Return On Asset: | Sell | |
DE: | Strong Buy | |
P/E: | Strong Sell | |
Price To Book: | Strong Buy |
QUARTER GROWTHS | ||||||
---|---|---|---|---|---|---|
3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
Revenue | n/a | n/a | n/a | |||
Gr.Profit | n/a | |||||
Ebit | ||||||
Asset | ||||||
Debt |
PE RATIO: COMPANY / SECTOR |
---|
0.00x |
Company: PE -3.54 | sector: PE -3.05 |
PE RATIO: COMPANY / INDUSTRY |
---|
-0.60x |
Company: PE -3.54 | industry: PE 5.88 |
DISCOUNTED CASH FLOW VALUE |
---|
$3.62 (-27.93%) $-1.402 |
Date: 2024-03-28 |
Expected Trading Range (DAY) |
---|
$ 4.68 - 5.36 ( +/- 6.71%) |
ATR Model: 14 days |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-01-18 | Nokes Rachael | Buy | 62 755 | Stock Option (right to buy) |
2024-01-18 | Nokes Rachael | Buy | 41 840 | Common Stock |
2024-01-18 | Tucker John H | Buy | 113 560 | Common Stock |
2024-01-18 | Tucker John H | Buy | 170 340 | Stock Option (right to buy) |
2024-01-02 | Nokes Rachael | Sell | 1 027 | Common Stock |
INSIDER POWER |
---|
32.64 |
Last 97 transactions |
Buy: 5 276 533 | Sell: 2 188 570 |
Indicator Signals | |
---|---|
RSI 21 | |
SMA | |
Trend | |
Trend 2 | |
Trend 3 | |
MACD |
Volume Signals | |
---|---|
Price | $5.02 (-0.20% ) |
Volume | 0.110 mill |
Avg. Vol. | 0.242 mill |
% of Avg. Vol | 45.52 % |
Signal 1: | |
Signal 2: |
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
Date | Signal | @ | Closed | % | Feb 8 - 15:34 | sell | $5.13 | N/A | Active |
---|
scPharmaceuticals Inc., a pharmaceutical company, engages in the development and commercialization of various pharmaceutical products. The company's lead product candidate is FUROSCIX that consists of formulation of furosemide, which is delivered through an on-body infusor for treatment of congestion in patients with heart failure. Its product pipeline also includes scCeftriaxone, an antibiotic to treat infections caused by gram-positive and gram-negative organisms; and scCarbapenem program, an antibiotic for treating infections caused by gram-negative organisms. The company has a development agreement with West Pharmaceutical Services, Inc. for development of single use SmartDose device. scPharmaceuticals Inc. was incorporated in 2013 and is headquartered in Burlington, Massachusetts.